Gamida Cell
About Us
Gamida Cell is a cell therapy pioneer working to turn cells into powerful therapeutics. Our proprietary nicotinamide (NAM) technology leverages the properties of NAM to enhance and expand cells, creating allogeneic cell therapy products and candidates that are potentially curative for patients with hematologic malignancies. Omisirge® (omidubicel-onlv), our nicotinamide modified allogeneic hematopoietic progenitor cell therapy was approved by the US FDA in April 2023 for the treatment of hematologic malignancies. Preliminary results in an ongoing multicenter Phase 1 study for GDA-201, our intrinsic NK cell therapy candidate, were announced in October 2023, and full results are expected in Q1 2024.
Investor and Media Contact
Ryan Pugliares
Gamida Cell Ltd.
IRPR@gamida-cell.com
Medical Information: medicalinformation@gamida-cell.com